Table 1.
Demographic. Clinical disease characteristics and medication history of the patients in UC patients.
| North American | Chilean | P value | |
|---|---|---|---|
| N | 65 45 (69%) Caucasian/1 (1%) African American/18 (28%) Hispanic-Latin/1 (1%) Middle Eastern |
108 104 (96%) Latin/4 (4%) Latin-Mapuche |
|
| Age, yr,* median (max–min) | 42 (19–88) | 40 (16–77) | NS |
| Duration of Disease, yr, median (max–min) | 10 (0–35) | 6 (0–53) | .01 |
| Age at diagnosis, yr, median (max–min) | 28 (11–62) | 31 (10–77) | NS |
| Sex | Female 18 (28%)/Male 47 (72%) | Female 68 (63%)/Male 40 (37%) | <.0001 |
| Smoking (yes/no/no data) | 1 (2%)/39 (60%)/25 (38%) | 19 (18%)/88 (81%)/1 (1%) | .01 |
| Surgery (yes/no) | 4 (6%)/61 (94%) | 7 (6%)/101 (94%) | NS |
| History of hospitalization (yes/no/no data) | 22 (34%)/14 (22%)/29 (45%) | 55 (51%)/53 (49%) | NS |
| Family history of IBD (yes/no/no data) | 4 (6%)/44 (68%)/17 (26%) | 8 (7%)/98 (91%)/2 (2%) | NS |
| Montreal UC | <.0001 | ||
| Extensive colitis (E3) | 37 (57%) | 54 (50%) | |
| Left colitis (E2) | 7 (11%) | 27 (25%) | |
| Proctitis (E1) | 0 (0%) | 27 (25%) | |
| No data registered | 21 (32%) | 0 | |
| White cell count ×106/L (normal range 4000–11,000), mean (max–min) | 7150 (3800–12,800) | 6825 (3400–21,440) | NS |
| Hemoglobin (g/L)* (normal range 12–18), mean (max–min) | 13.4 (8.5–16.7) | 13.3 (7.1–16.9) | NS |
| Platelets, ×106/L (normal range 150,000–450,000), mean (max–min) | 269,000 (134,000–564,000) | 285,500 (57,000–601,000) | NS |
| C reactive protein (mg/dL) normal range < 0.5 | 3 (0.03–8) | 6 (0.03–15.88) | .01 |
| Erythrocyte sedimentation rate (mm/h) normal range < 30 | 8 (2–28) | 9 (1–86) | NS |
| Albumin (g/L) normal range (3.5–5.5) | 4.3 (3–4.6) | 4.5 (2.5–5.2) | .008 |
| Total Mayo Score | 1 (011) | 2 (0–9) | NS |
| Endoscopic Mayo score 0/1/2/3/NA | 25/10/2/2/22 | 32/25/38/13 | .0002 |
| Current therapies (yes/no/no data) | |||
| Steroids | 13 (20%)/52 (80%) | 15 (14%)/93 (86%) | NS |
| Biological | 30 (46%)/35 (%4%) | 9 (8.3%)/99 (91.7%) | <.0001 |
| Anti-TNF-α | 18 (28%)/47 (72%) | 9 (8.3%)/99 (91.7%) | .001 |
| Immunomodulators | 22 (34%)/43 (66%) | 38 (35%)/69 (64%)/1 (1%) | NS |
| Aminosalicylates | 16 (35%)/49 (65%) | 84 (77%)/24 (22%)/1 (1%) | <.0001 |
| History of therapies | |||
| Steroids | 47 (72%)/3 (5%)/15 (23%) | 89 (82%)/13 (12%)/6 (6%) | NS |
| Immunomodulators | 31 (48%)/14 (22%)/20 (30%) | 53 (49%)/49 (45%)/6 (6%) | NS |
| Biological therapies | 36 (55%)/9 (14%)/20 (31%) | 18 (17%)/84 (83%) | <.0001 |
| Naive anti-TNF-α | 13 (20%)/52 (80%) | 91 (84%)/17 (16%) | <.0001 |
IBD = inflammatory bowel disease, NS = not significant, TNF = tumor necrosis factor, UC = ulcerative colitis.